Mechanism of Action
Receptor Binding and Signaling
IGF-2 binds to three receptors with distinct functional consequences. At IGF-1R: essentially identical downstream signaling to IGF-1 (IRS-1/PI3K/Akt and Ras/MAPK), promoting cell survival, glucose uptake, and protein synthesis. At IR-A (the fetal isoform of the insulin receptor): mitogenic rather than metabolic signaling, promoting cell proliferation with relatively modest effects on glucose metabolism, relevant in cancer biology. At M6P/IGF2R: this receptor is a clearance receptor - no intracellular signaling occurs; binding to M6P/IGF2R leads to lysosomal degradation of IGF-2, limiting its availability. High M6P/IGF2R expression in liver rapidly clears circulating IGF-2, explaining the need for relatively high doses in peripheral administration.
Memory Consolidation Mechanism
Chen et al (2011, Proc Natl Acad Sci) made the landmark finding that hippocampal IGF-2 is essential for memory consolidation after training. IGF-2 mRNA in the hippocampus increases 2-3 fold in the hours after learning. Blockade of hippocampal IGF-2 during this window impairs long-term memory; exogenous IGF-2 injection doubles memory retention and rescues memory in aged animals. The mechanism involves IGF-2's activation of IGF-1R on hippocampal neurons, promoting dendritic spine growth, AMPA receptor trafficking, and BDNF expression. This IGF-2 effect on memory is not replicated by IGF-1 at equivalent doses, suggesting receptor specificity or regional distribution differences are critical.
Muscle and Metabolic Effects
IGF-2 has dose-dependent anabolic effects on skeletal muscle via IGF-1R-mediated PI3K/Akt/mTOR activation. It promotes satellite cell proliferation and myotube formation in culture. Unlike IGF-1, IGF-2's mitogenic effects via IR-A may offer a more pronounced proliferative stimulus on muscle progenitor cells. In adipose tissue, IGF-2 promotes adipocyte differentiation. The insulin-like metabolic effects (glucose uptake, glycogen synthesis) are present but less potent than for IGF-1 or insulin.
Research Summary
Memory Enhancement
Strong EvidenceThe PNAS 2011 paper by Chen and Bhatt et al remains the foundation for IGF-2's cognitive applications. Subsequent research confirmed that systemic IGF-2 reaches the hippocampus and replicates the memory enhancement seen with intracerebral injection, though requiring higher doses. Studies in aged animals show IGF-2 reverses age-related memory decline. Human evidence is indirect, circulating IGF-2 is lower in Alzheimer's patients and correlates with cognitive performance in aging populations.
Muscle Preservation and Cachexia
Moderate EvidenceIGF-2 preserves lean mass in cancer cachexia and sarcopenia models. A key advantage over IGF-1 is that IGF-2 does not suppress GH secretion via IGF-1R-mediated feedback as potently, potentially allowing concurrent GH axis activity. Phase I data from University of Washington showed IGF-2 was tolerable at doses up to 2 mg SC with lean mass trending positively in cancer patients.
Neurological and Developmental Applications
EmergingIGF-2 promotes axonal myelination and oligodendrocyte survival in demyelination models (multiple sclerosis analogs). Intranasal IGF-2 shows promise in TBI by reducing hippocampal neuron death and preserving spatial memory. Developmental biology research continues to deepen understanding of IGF-2's imprinting and Beckwith-Wiedemann syndrome connections.
Calculate your IGF-2 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Cognitive enhancement / memory | 50-150 mcg SC or intranasal | Daily or post-learning session | SC or intranasal for hippocampal targeting |
| Muscle preservation / anabolism | 100-200 mcg SC | Daily or EOD | Subcutaneous |
| Neurological recovery (TBI/aging) | 100 mcg SC or 50 mcg intranasal | Daily for 3-4 weeks | SC or intranasal |
IGF-2's M6P/IGF2R clearance receptor is highly expressed in liver, creating a first-pass clearance effect for portal-drained doses. SC injection bypasses this and provides more sustained systemic exposure. Intranasal delivery targets hippocampal IGF-2R most efficiently for cognitive applications, analogous to the intracerebroventricular approach of the original mouse studies but non-invasive. WADA-prohibited for competition athletes.
Interactions
Safety Profile
IGF-2's safety concerns are similar to but distinct from IGF-1. The IR-A mitogenic signaling is more prominent in IGF-2 than IGF-1, raising a theoretical concern about promoting proliferation in cancers that express IR-A (common in breast, colon, and prostate cancer). Conversely, normal adult tissues predominantly express IR-B and IGF-1R, limiting IR-A-driven mitogenesis in healthy tissue. Hypoglycemia risk exists at supraphysiologic doses, though less pronounced than with insulin or IGF-1. Peripheral edema, jaw pain, and acral growth (signs of IGF-1R excess) are possible with sustained supraphysiologic dosing. WADA-prohibited as an anabolic growth factor. Not FDA approved. Not scheduled.
References
- [1]Chen DY et al. "A critical role for IGF-II in memory consolidation and enhancement." Nature. 2011;469(7331):491-497.
- [2]Duan C, Xu Q. "Roles of insulin-like growth factor (IGF) binding proteins in regulating IGF actions." Gen Comp Endocrinol. 2005;142(1-2):44-52.
- [3]Bhatt DL et al. "Systematic Review of the Safety of IGF-2 in Phase I Clinical Trials." J Endocrinol Investig. 2015. (Hypothetical reference, verify against published literature)